By Cecilia Butini
Valneva has received positive safety data in a Phase 3 trial studying a vaccine against the mosquito-borne chikungunya virus.
Data showed that the shot was generally safe and well tolerated in adolescents between 12 and 17 years of age, the French pharmaceutical company said Monday.
At 0813 GMT, Valneva shares were up 2.4% after rising as much as 5% in early trading.
Write to Cecilia Butini at [email protected]
Read the full article here
